Literature DB >> 8388286

Cimetidine suspension as adjuvant to energy restricted diet in treating obesity.

M H Rasmussen1, T Andersen, L Breum, P C Gøtzsche, J Hilsted.   

Abstract

OBJECTIVE: To study the effect of cimetidine suspension compared with placebo suspension on weight loss in moderately obese patients taking a 5 MJ/day diet supplemented with dietary fibre. To determine the relation between the effectiveness of the blinding and weight loss.
DESIGN: Randomised double blind study with an eight week parallel group phase and a subsequent eight week crossover or continuation phase.
SETTING: Outpatient clinic.
SUBJECTS: 60 patients (51 women) aged 18-60. MAIN OUTCOME MEASURE: Weight loss.
RESULTS: After eight weeks of treatment the mean weight loss in the cimetidine group (5.7 kg) was similar to that of the placebo group (5.9 kg; p = 0.78, 95% confidence interval -2.0 to 1.5 kg). Body mass index, waist and hip measurements, waist-hip ratio, and systolic and diastolic blood pressures decreased similarly in the two groups. No association was found between weight loss and the patients' ability to guess if they were being given drug or placebo. Correct guesses of current drug were more prevalent than expected by chance (25/37 correct, p = 0.05 for the parallel group phase; 26/30, p = 0.0001 for the crossover phase).
CONCLUSIONS: Cimetidine had no effect on weight loss in moderately obese patients. The study underlines the potential problem that blinding of patients to treatment can be compromised.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388286      PMCID: PMC1677486          DOI: 10.1136/bmj.306.6885.1093

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  8 in total

1.  THE FEET OF CLAY OF THE DOUBLE-BLIND TRIAL.

Authors:  B W CROMIE
Journal:  Lancet       Date:  1963-11-09       Impact factor: 79.321

2.  The controlled clinical trial: theory and practice.

Authors:  L LASAGNA
Journal:  J Chronic Dis       Date:  1955-04

3.  The double-blind procedure: rationale and empirical evaluation.

Authors:  H NASH
Journal:  J Nerv Ment Dis       Date:  1962-01       Impact factor: 2.254

4.  Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis.

Authors:  P C Gøtzsche
Journal:  Control Clin Trials       Date:  1989-03

5.  Regional obesity and serum lipids in European women born in 1948. A multicenter study.

Authors:  J C Seidell; M Cigolini; J Charzewska; B M Ellsinger; F Contaldo
Journal:  Acta Med Scand Suppl       Date:  1988

6.  Crossover and self-controlled designs in clinical research.

Authors:  T A Louis; P W Lavori; J C Bailar; M Polansky
Journal:  N Engl J Med       Date:  1984-01-05       Impact factor: 91.245

7.  Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial.

Authors:  T Andersen; A Astrup; F Quaade
Journal:  Int J Obes Relat Metab Disord       Date:  1992-01

8.  The double-blind in danger: untoward consequences of informed consent.

Authors:  K D Brownell; A J Stunkard
Journal:  Am J Psychiatry       Date:  1982-11       Impact factor: 18.112

  8 in total
  5 in total

Review 1.  Options for the management of obesity.

Authors:  P L Beales; P G Kopelman
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

2.  Does cimetidine cause weight loss?

Authors:  J Garrow
Journal:  BMJ       Date:  1993-04-24

3.  Cimetidine and weight loss.

Authors:  P Mangtani; P Seed
Journal:  BMJ       Date:  1993-06-05

Review 4.  Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.

Authors:  S L Norris; X Zhang; A Avenell; E Gregg; C H Schmid; J Lau
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

Review 5.  Research misconduct: the poisoning of the well.

Authors:  Richard Smith
Journal:  J R Soc Med       Date:  2006-05       Impact factor: 18.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.